Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Rev. bras. enferm ; 72(3): 760-766, May.-Jun. 2019. tab
Article in English | LILACS, BDENF | ID: biblio-1013564

ABSTRACT

ABSTRACT Objective: To evaluate the risk factors related to Klebsiella pneumoniae carbapenemase infection after renal transplantation. Methods: This was a retrospective epidemiological (case-control) study, conducted from October 2011 to march 2016. Transplanted patients with infection by this bacteria during hospitalization were selected as cases. The controls were paired by age, sex, type of donor and transplant time. The proportion of cases and controls was 1:2. Results: Thirty hundred and five patients were included in the study (45 cases and 90 controls). The risk factors found for infection by KPC were: time of hospitalization after the transplant (OR: 4.82; CI95% 2.46-9.44), delayed kidney function (OR: 5.60; CI95% 1.91-11.01) and previous infectious for another microorganism ( OR: 34.13 CI95% 3.52-132.00). Conclusion: The risk of acquisition of this bacterium was directly related to invasive procedures and exposure to the hospital environment. The findings reinforce the importance of prevention measures and control of infection by this microorganism.


RESUMEN Objetivo: Evaluar los factores de riesgo relacionados con la infección por Klebsiella pneumoniae carbapenemasa después del trasplante renal. Método: Estudio retrospectivo epidemiológico (caso-control), realizado de octubre de 2011 a marzo de 2016. Pacientes transplantados con infección por esa bacteria durante la internación fueron seleccionados como casos. Los controles se parearon por edad, sexo, tipo de donante y tiempo de trasplante. La proporción de casos y controles fue de 1: 2. Resultados: Treinta y cinco pacientes fueron incluidos en el estudio (45 casos y 90 controles). Los factores de riesgo para la infección encontrados por KPC fueron: tiempo de hospitalización después del trasplante (OR: 4,82, IC95% 2,46-9,44), función renal retardada (OR: 5,60, IC95% 1, 91-11,01) y anterior infecciosa para otro microorganismo (OR: 34,13 IC95% 3,52-132,00). Conclusión: El riesgo de adquisición de esta bacteria estuvo directamente relacionado a procedimientos invasivos y exposición al ambiente hospitalario. Los hallazgos refuerzan la importancia de medidas de prevención y control de la infección por ese microorganismo.


Subject(s)
Humans , Male , Female , Adult , Pneumonia/ethnology , Bacterial Proteins/adverse effects , beta-Lactamases/adverse effects , Klebsiella Infections/etiology , Kidney Transplantation/adverse effects , Pneumonia/chemically induced , Pneumonia/epidemiology , Bacterial Proteins/metabolism , beta-Lactamases/metabolism , Brazil/epidemiology , Klebsiella Infections/metabolism , Klebsiella Infections/epidemiology , Case-Control Studies , Retrospective Studies , Risk Factors , Kidney Transplantation/methods , Klebsiella pneumoniae/metabolism , Klebsiella pneumoniae/pathogenicity , Middle Aged
2.
Braz. j. med. biol. res ; 45(12): 1183-1194, Dec. 2012. ilus, mapas, tab
Article in English | LILACS | ID: lil-659642

ABSTRACT

In the last several years, the use of dendritic cells has been studied as a therapeutic strategy against tumors. Dendritic cells can be pulsed with peptides or full-length protein, or they can be transfected with DNA or RNA. However, comparative studies suggest that transfecting dendritic cells with messenger RNA (mRNA) is superior to other antigen-loading techniques in generating immunocompetent dendritic cells. In the present study, we evaluated a new therapeutic strategy to fight tuberculosis using dendritic cells and macrophages transfected with Hsp65 mRNA. First, we demonstrated that antigen-presenting cells transfected with Hsp65 mRNA exhibit a higher level of expression of co-stimulatory molecules, suggesting that Hsp65 mRNA has immunostimulatory properties. We also demonstrated that spleen cells obtained from animals immunized with mock and Hsp65 mRNA-transfected dendritic cells were able to generate a mixed Th1/Th2 response with production not only of IFN-γ but also of IL-5 and IL-10. In contrast, cells recovered from mice immunized with Hsp65 mRNA-transfected macrophages were able to produce only IL-5. When mice were infected with Mycobacterium tuberculosis and treated with antigen-presenting cells transfected with Hsp65 mRNA (therapeutic immunization), we did not detect any decrease in the lung bacterial load or any preservation of the lung parenchyma, indicating the inability of transfected cells to confer curative effects against tuberculosis. In spite of the lack of therapeutic efficacy, this study reports for the first time the use of antigen-presenting cells transfected with mRNA in experimental tuberculosis.


Subject(s)
Animals , Male , Mice , Antigen-Presenting Cells/immunology , Bacterial Proteins/administration & dosage , /administration & dosage , Mycobacterium tuberculosis/immunology , RNA, Messenger/immunology , Tuberculosis Vaccines/administration & dosage , Tuberculosis/immunology , Bacterial Proteins/adverse effects , Bacterial Proteins/immunology , /adverse effects , /immunology , Mice, Inbred BALB C , RNA, Messenger/adverse effects , Spleen/immunology , Transfection , Tuberculosis Vaccines/adverse effects , Tuberculosis Vaccines/immunology , Tuberculosis/prevention & control
3.
Indian J Exp Biol ; 1995 Aug; 33(8): 545-51
Article in English | IMSEAR | ID: sea-61001

ABSTRACT

Promises and limitations in exploitation of microorganisms for single cell protein (SCP) production have been reviewed. Various aspects discussed include global protein problem, microbes as potential sources of food and feed with its advantages and disadvantages, salient features in selection of microorganisms for SCP production, production of SCP from petroleum based hydrocarbons, renewable raw materials like agricultural and forestry residues, industrial by-products and wastes, nutritional and safety evaluation of SCP, ways of improving SCP production, economics of SCP production and the present status of SCP in India.


Subject(s)
Bacterial Proteins/adverse effects , Dietary Proteins/adverse effects , Glycoproteins/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL